{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:27:45Z","timestamp":1761920865048,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00415-021-10556-z","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T05:59:01Z","timestamp":1618466341000},"page":"3975-3979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?"],"prefix":"10.1007","volume":"268","author":[{"given":"Mario","family":"Orrico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Nozzolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"10556_CR1","volume-title":"Features, evaluation and treatment coronavirus (COVID-19) [Updated 2020 Oct 4]. In: StatPearls [Internet]","author":"M Cascella","year":"2020","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation and treatment coronavirus (COVID-19) [Updated 2020 Oct 4]. In: StatPearls [Internet]. StatPearls Publishing"},{"key":"10556_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2581","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2581","journal-title":"JAMA Neurol"},{"key":"10556_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000753","author":"M Barzegar","year":"2020","unstructured":"Barzegar M, Mirmosayyeb O, Nehzat N et al (2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod Neurology. Neuroimmunol Neuroinflam. https:\/\/doi.org\/10.1212\/NXI.0000000000000753","journal-title":"Neuroimmunol Neuroinflam"},{"key":"10556_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102180","author":"C Foerch","year":"2020","unstructured":"Foerch C, Friedauer L, Bauer B et al (2020) Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2020.102180","journal-title":"Mult Scler Relat Disord"},{"key":"10556_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26279","author":"V Gomez-Mayordomo","year":"2020","unstructured":"Gomez-Mayordomo V, Montero-Escribano P, Mat\u00edas-Guiu J et al (2020) Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26279","journal-title":"J Med Virol"},{"key":"10556_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B et al (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73:790\u2013794. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"key":"10556_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","volume":"168","author":"J Camm","year":"2014","unstructured":"Camm J, Hla T, Bakshi R et al (2014) Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J 168:632\u2013644. https:\/\/doi.org\/10.1016\/j.ahj.2014.06.028","journal-title":"Am Heart J"},{"key":"10556_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.msard.2015.10.009","volume":"5","author":"J Datt","year":"2016","unstructured":"Datt J, Baldock L, Pull E et al (2016) The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 5:40\u201346. https:\/\/doi.org\/10.1016\/j.msard.2015.10.009","journal-title":"Mult Scler Relat Disord"},{"key":"10556_CR9","doi-asserted-by":"publisher","first-page":"310597","DOI":"10.1136\/jnnp-2015-310597","volume":"215","author":"JA Cohen","year":"2015","unstructured":"Cohen JA, Khatri B, Barkhof F et al (2015) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 215:310597. https:\/\/doi.org\/10.1136\/jnnp-2015-310597","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10556_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1124\/dmd.110.035378","volume":"39","author":"Y Jin","year":"2011","unstructured":"Jin Y, Zollinger M, Borell H et al (2011) CYP4F Enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Disposition 39(2):191\u2013198. https:\/\/doi.org\/10.1124\/dmd.110.035378","journal-title":"Drug Metab Disposition"},{"issue":"20","key":"10556_CR11","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1158\/0008-5472.CAN-03-2677","volume":"64","author":"T Ikezoe","year":"2004","unstructured":"Ikezoe T, Hisatake Y, Takeuchi T et al (2004) HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4 enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res Actions 64(20):7426\u20137431. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-2677","journal-title":"Cancer Res Actions"},{"issue":"2","key":"10556_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/dmd.109.028746","volume":"38","author":"SK Quinney","year":"2010","unstructured":"Quinney SK, Zhang X, Lucksiri A et al (2010b) Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38(2):241\u2013248. https:\/\/doi.org\/10.1124\/dmd.109.028746","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10556_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HS (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91\u2013101. https:\/\/doi.org\/10.1097\/WNF.0b013e3181cbf825","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10556_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1541-7786.MCR-08-0156","volume":"7","author":"SE Schnitzer","year":"2009","unstructured":"Schnitzer SE, Weigert A, Zhou J et al (2009) Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res Actions 7(3):393\u2013401. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0156","journal-title":"Mol Cancer Res Actions"},{"key":"10556_CR15","doi-asserted-by":"publisher","first-page":"12086","DOI":"10.1038\/ncomms12086","volume":"7","author":"K Sun","year":"2016","unstructured":"Sun K, Zhang J, Dalessandro A et al (2016) Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia. Nat Commun 7:12086. https:\/\/doi.org\/10.1038\/ncomms12086","journal-title":"Nat Commun"},{"issue":"4","key":"10556_CR16","doi-asserted-by":"publisher","first-page":"e0123437","DOI":"10.1371\/journal.pone.0123437","volume":"10","author":"PA Williams","year":"2015","unstructured":"Williams PA, Stilhano RS, To VP et al (2015) Hypoxia augments outgrowth endothelial cell (OEC) sprouting and directed migration in response to sphingosine-1-phosphate (S1P). PLoS ONE 10(4):e0123437. https:\/\/doi.org\/10.1371\/journal.pone.0123437","journal-title":"PLoS ONE"},{"issue":"1","key":"10556_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbalip.2012.06.006","volume":"1831","author":"JS Karliner","year":"2013","unstructured":"Karliner JS (2013) Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 1831(1):203\u2013212. https:\/\/doi.org\/10.1016\/j.bbalip.2012.06.006","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10556_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cmet.2020.06.016","volume":"32","author":"JW Song","year":"2020","unstructured":"Song JW, Lam SM, Fan X et al (2020) Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab 32(2):188-202.e5. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.016","journal-title":"Cell Metab"},{"issue":"1","key":"10556_CR19","doi-asserted-by":"publisher","first-page":"e13424","DOI":"10.15252\/emmm.202013424","volume":"13","author":"G Marfia","year":"2020","unstructured":"Marfia G, Navone S, Guarnaccia L et al (2020) Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19. EMBO Mol Med 13(1):e13424. https:\/\/doi.org\/10.15252\/emmm.202013424","journal-title":"EMBO Mol Med"},{"key":"10556_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","volume":"30","author":"JG Cyster","year":"2012","unstructured":"Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30:69\u201394. https:\/\/doi.org\/10.1146\/annurev-immunol-020711-075011","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10556_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13054-015-1089-0","volume":"19","author":"A Mudersbach","year":"2015","unstructured":"Mudersbach A, Robbe BL et al (2015) Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care 19(2):372. https:\/\/doi.org\/10.1186\/s13054-015-1089-0","journal-title":"Crit Care"},{"key":"10556_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10556-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10556-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10556-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T15:36:14Z","timestamp":1633966574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10556-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10556"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10556-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Orrico, S. Gelibter and A. Nozzolillo have no conflicts of interest to report. F. Sangalli has received speaker\u2019s honoraria and travel support form Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and TEVA. P. Preziosa received speaker honoraria from Biogen Idec, Novartis, Merck Serono and ExceMED. L. Moiola has received speaker\u2019s honoraria from the following companies: Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and TEVA. M. Filippi is Editor-in-Chief of the <i>Journal of Neurology<\/i>\u00a0and Associate Editor of <i>Human Brain Mapping<\/i>; received compensation for consulting services and\/or speaking activities from Almiral, Alexion, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Itali- ana di Ricerca per la SLA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}